Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 5 HR for the Secondary End Point at 2 Years in Quartiles of Baseline LDL-C
A progressive decrease in the benefit of atorvastatin 80 mg over pravastatin 40 mg with respect to the secondary end point was seen from the highest to the lowest baseline LDL-C quartile. Significant adjusted interactions for the outcome were seen between therapy and quartiles 1 and 4 (p = 0.007), 2 and 4 (p = 0.02), and 3 and 4 (p = 0.05). Abbreviations as in Figures 1 and 3.
|
